Make sure that you and your doctor use the bone-protecting approved medications (zoledronic acid or denosumab), especially for at least three weeks before using Xofigo (Radium-223).
Sub-group analysis of the clinical trial ERA 223 signal that the concerns about the use in combination of Zytiga and Xofigo might not cause a significant increase in the risk for developing bone fractures if a man is also simultaneously on a bone targeted therapy.
In a small, 25 man, but significant clinical trial of men with metastatic castrate-resistant prostate cancer (mCRPC) who also qualified for Radium-223 (Xofigo) it was shown that the level of pain a man has during the treatment could be used as a prognostic tool of his survival.
There are two phase 1 and 2 clinical trials reporting about a new PSMA targeting alpha emitting investigational radiation treatment. The trials are are very promising. They evaluate a new investigational treatment called Ac-225-PSMA-617.
We now need to wait for a phase 3 trial.
The European Medicines Agency (EMA) has recommended that the use of Xofigo (Radium-223) be restricted. The restrictions, because of safety and efficacy concerns in men with castrate resistant prostate cancer (mCRPC), include that Xofigo can be used only after two other treatments have been taken; when other therapies cannot be used and not in combination with other 2nd line hormone therapies.
The European Medicines Agency (EMA) has recommended halting the use of the Xofigo (radium-223 dichloride) in combination with Zytiga (abiraterone acetate) and prednisone due to a possible increased risk of death and fractures.
For men who have aggressive advanced prostate cancer and have "burned through' many other treatments an investigation radiotherapy treatment called LU-177 holds the potential for extending their life and improving its quality.